Reviewed by Michael Gill, B. Sc.
Image of Ohio University Exercise Physiology Lab in Athens, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Tart Cherryfor Metabolic Syndrome

18 - 65
All Sexes
Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease target. The primary treatment for MetSyn is exercise and weight loss, along with medically necessary treatment. Exercise, along with dietary changes such as increased fiber and polyphenol intake can positively impact many of the metabolic abnormalities seen with MetSyn. For example, polyphenols have been shown to decrease lipid concentration and improved glucose clearance as well as decreased oxidative stress and inflammation. Powdered tart cherry capsules, which contain the skin of the fruit, provides polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation, providing energy substrates and barrier integrity to the colonocytes and increasing the bioavailability of the polyphenols to other cells in the body. However there have been no long-term investigations into the use of powdered tart cherry supplements in MetSyn, therefore we aim to determine if 60 days tart cherry supplementation modify criteria for MetSyn in currently diagnosed individuals including body mass, waist circumference, blood pressure, blood lipid levels and blood glucose control.
Recruiting
New This Month
Ohio University Exercise Physiology Lab
25 Metabolic Syndrome Clinical Trials Near Me
Top Hospitals for Metabolic Syndrome Clinical Trials
Image of University of Virginia in Virginia.
University of Virginia
Charlottesville
3Active Trials
4All Time Trials for Metabolic Syndrome
2014First Metabolic Syndrome Trial
Image of USDA Western Human Nutrition Research Center in California.
USDA Western Human Nutrition Research Center
Davis
2Active Trials
2All Time Trials for Metabolic Syndrome
2012First Metabolic Syndrome Trial
Top Cities for Metabolic Syndrome Clinical Trials
Image of Toronto in Ontario.
Toronto
6Active Trials
University Health Network - Toronto General HospitalTop Active Site
Metabolic Syndrome Clinical Trials by Phase of Trial
Phase 1 Metabolic Syndrome Clinical Trials
2Active Metabolic Syndrome Clinical Trials
2Number of Unique Treatments
1Number of Active Locations
Freeze-dried strawberry powderAngiotensin-(1-7)
Metabolic Syndrome Clinical Trials by Age Group
18+ Metabolic Syndrome Clinical Trials
55Active Metabolic Syndrome Clinical Trials
Collaborative Diet Goal Setting Clinical Decision SupportFreeze-dried strawberry powderDiet InterventionHIFT 1x/weekExercise TrainingS.L.I.M.M.S. ProcedureKetone Ester drink/ Arm 1Genotype of interest group
Most Recent Metabolic Syndrome Clinical Trials
Top Treatments for Metabolic Syndrome Clinical Trials
Treatment Name
Active Metabolic Syndrome Clinical Trials
All Time Trials for Metabolic Syndrome
First Recorded Metabolic Syndrome Trial
Metformin
3
20
2006
Exercise
2
13
2004
Control
2
18
2001
Collaborative Diet Goal Setting Clinical Decision Support
1
1
2022
Freeze-dried strawberry powder
1
1
2023

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. https://pubmed.ncbi.nlm.nih.gov/84333902 Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985 Sep;10(3):141-6. https://pubmed.ncbi.nlm.nih.gov/40532613 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. https://pubmed.ncbi.nlm.nih.gov/38998254 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17. Erratum in: Circulation. 2015 Jun 16;131(24):e535. Circulation. 2016 Feb 23;133(8):e417. https://pubmed.ncbi.nlm.nih.gov/255203745 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. https://pubmed.ncbi.nlm.nih.gov/113687026 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5. https://pubmed.ncbi.nlm.nih.gov/198056547 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558. https://pubmed.ncbi.nlm.nih.gov/97429778 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5. https://pubmed.ncbi.nlm.nih.gov/198056549 Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. https://pubmed.ncbi.nlm.nih.gov/1664470210 Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380. https://pubmed.ncbi.nlm.nih.gov/9863851